# US Protein Therapeutics Market > US Protein Therapeutics Market Research Report By Type (Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon), By Application (Cancer, Metabolic Disorders, Immunologic Disorders, Hematological Disorders) and By End User (Hospitals and Clinics, Specialty Centers) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 7.36% - **2024:** $ 46.74 Billion - **2025:** $ 50.18 Billion - **2035:** $ 102.08 Billion - **Key Players:** Amgen (US), Genentech (US), AbbVie (US), Roche (CH), Bristol-Myers Squibb (US), Eli Lilly (US), Sanofi (FR), Merck & Co. (US), Novo Nordisk (DK) **Report ID:** MRFR/LS/18156-HCR · **Pages:** 100 · **Author:** Vikita Thakur & Garvit Vyas · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-protein-therapeutics-market-19703 --- ## Market Summary ## **US Protein Therapeutics Market Overview** As per MRFR analysis, the US Protein Therapeutics Market Size was estimated at 49.55 (USD Billion) in 2023. The US Protein Therapeutics Market Industry is expected to grow from 52.97(USD Billion) in 2024 to 110.59 (USD Billion) by 2035. The US Protein Therapeutics Market CAGR (growth rate) is expected to be around 6.921% during the forecast period (2025 - 2035). ### **Key US Protein Therapeutics Market Trends Highlighted** The US Protein Therapeutics Market is witnessing notable trends driven by advancements in biotechnology and an increasing demand for targeted therapies. One of the key market drivers is the rising prevalence of chronic diseases and genetic disorders, leading to a growing need for innovative biologics that offer more effective treatment options. Regulatory support from agencies such as the Food and Drug Administration (FDA) encourages the development of protein therapeutics, providing a smoother pathway for bringing new therapies to the market. Opportunities to be explored include the rise in personalized medicine, where therapies are tailored to individual patient genetics, thus improving efficacy and reducing side effects. There is also an increased focus on biosimilars, as they offer a cost-effective alternative to expensive biologic drugs, which can enhance accessibility for patients. The expansion of biologics manufacturing capabilities in the US is further bolstered by investments in research and development, creating a conducive environment for innovation. Trends in recent times reflect a heightened interest in combination therapies that utilize protein therapeutics alongside other treatment modalities, paving the way for improved patient outcomes. Additionally, advancements in gene therapy and regenerative medicine are transforming the landscape, enabling the development of novel protein therapies for previously untreatable conditions. The US is becoming a hub for clinical trials, providing robust infrastructure to support research activities. This environment is further complemented by collaborations between academia, private industry, and government institutions, enhancing the overall productivity of the protein therapeutics sector. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **US Protein Therapeutics Market Drivers** ### **Increasing Prevalence of Chronic Diseases** The rise in chronic diseases such as cancer, diabetes, and autoimmune disorders is a significant driver of the US [Protein Therapeutics Market](../../../reports/protein-therapeutics-market-10142) Industry. According to the Centers for Disease Control and Prevention (CDC), approximately 60% of adults in the United States have at least one chronic disease, with this number projected to increase as the population ages. The American Cancer Society has reported that over 1.8 million new cancer cases are expected in the US in 2023 alone, highlighting the urgent need for innovative therapeutics. As protein therapeutics are frequently utilized in treating these conditions, the growing patient population will spur demand for these treatments. Established companies like Amgen and Genentech are actively involved in developing protein-based therapeutics aimed at addressing these chronic illnesses, thus reinforcing the positive outlook for the market's growth driven by the increasing burden of diseases. ### **Advancements in Biotechnology and Research** Technological innovations and advancements in biotechnology play a pivotal role in the growth of the US Protein Therapeutics Market Industry. The National Institutes of Health reported significant increases in funding for Research and Development (R&D) activities, reaching approximately $43 billion in 2022, which creates a conducive environment for protein therapeutics innovations. This influx of funds enables companies to explore new therapeutic proteins and enhance existing modalities. Organizations such as the Biotechnology Innovation Organization are also working to streamline processes for bringing these products to market. As new technologies evolve, the efficiency and efficacy of protein therapeutics improve, attracting more investment and accelerating market expansion. ### **Growing Demand for Personalized Medicine** The trend towards personalized medicine is significantly influencing the US Protein Therapeutics Market Industry. The National Cancer Institute has indicated that tailored therapies could provide better outcomes for patients by considering individual variations in genes and proteins. The demand for personalized medicine is evident, with projections suggesting that the market for this sector could exceed $2.4 trillion by 2024. Companies like Regeneron Pharmaceuticals are pioneering this space, leveraging protein therapeutics to create customized treatment solutions. The increasing recognition of the benefits of personalized approaches in disease treatment will lead to heightened demand for innovative protein-based therapies, resulting in sustained market growth. ### **Supportive Regulatory Environment** The evolving regulatory landscape in the United States is assisting in the rapid development and approval of protein therapeutics. The Food and Drug Administration (FDA) has introduced initiatives such as 'Breakthrough Therapy Designation', which expedites the development process for therapies that show significant improvement over existing options. The FDA approved a record number of new therapies in the last few years, with over 50% of these being biologics, a category that includes many protein therapeutics. This supportive framework not only encourages new product development but also enhances market accessibility. Companies such as Bristol-Myers Squibb are benefitting from these regulatory advancements, streamlining their pathways to bringing transformative protein therapies to patients. ## **US Protein Therapeutics Market Segment Insights** ### **Protein Therapeutics Market Type Insights** The US Protein Therapeutics Market has been significantly shaped by its diverse Type segmentation, which includes Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, and Interferon. Each of these categories plays a vital role in addressing various health conditions and continues to witness a growing demand driven by advancements in biotechnology. Monoclonal Antibodies have emerged as a leading therapeutic modality, recognized for their specificity and efficacy in treating conditions such as cancer, autoimmune disorders, and infectious diseases. The ability to target disease-causing cells with precision has made Monoclonal Antibodies a cornerstone of modern therapeutics. Insulin remains a critical therapeutic protein for managing diabetes, a prevalent health issue in the United States. The rise in diabetes prevalence has resulted in a strong demand for insulin products, highlighting the importance of this segment in improving patient quality of life. Fusion Proteins serve to enhance pharmacokinetics and bioavailability, providing advantages such as extended half-life and improved patient adherence. With an increasing focus on personalized medicine, Fusion Proteins are gaining traction due to their ability to combine the beneficial properties of different therapeutic agents into a single product. Erythropoietin, known for its role in stimulating red blood cell production, is particularly significant in the treatment of anemia associated with chronic kidney disease and cancer therapies. This segment's relevance in managing these conditions reflects the ongoing focus on improving patient outcomes in chronic illnesses. Lastly, Interferon plays a pivotal role in the treatment of viral infections and certain types of cancer, validating its importance in the therapeutic arsenal. The regulatory landscape in the US, along with investments in Research and Development, continues to support the growth of these types, positioning the US Protein Therapeutics Market for steady expansion. Overall, the Type segmentation of the US Protein Therapeutics Market showcases a multifaceted approach to healthcare that aims to address a broad spectrum of medical needs while adapting to the evolving landscape of biotechnology and pharmaceutical innovations. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Protein Therapeutics Market Application Insights** The Application segment of the US Protein Therapeutics Market is increasingly vital, driven by the rising prevalence of various diseases such as cancer and metabolic disorders. Cancer treatments utilizing protein therapeutics have gained significant traction, addressing the critical need for effective therapies amidst growing incidences. Metabolic disorders are also on the rise, leading to an increased focus on protein-based treatments that can help in managing conditions like diabetes and obesity. Immunologic and hematological disorders further highlight the robustness of this market, as therapies targeting these ailments slowly fill healthcare gaps where traditional treatments may fall short. The US government and healthcare systems are recognizing the importance of tailoring protein therapeutics to meet specific patient needs, creating substantial opportunities for innovative solutions. This acknowledgment is critical for the ongoing advancements in the US Protein Therapeutics Market, as it positions the application of these therapeutics as a cornerstone in developing targeted and personalized medical treatments while showcasing the growing recognition of protein therapeutic roles within the biological spectrum of disease management.Continued developments in this market reflect its potential to significantly alter treatment landscapes for American patients. ### **Protein Therapeutics Market End User Insights** The End User segment of the US Protein Therapeutics Market encompasses various healthcare settings where therapeutic proteins are utilized, significantly including Hospitals and Clinics as well as Specialty Centers. Hospitals and Clinics serve as critical access points for patients receiving protein-based treatments, playing a vital role in the administration and monitoring of these therapies. With an increasing patient population demanding innovative biological therapies, hospitals are seeing intensified usage of protein therapeutics due to their clinical effectiveness and tailored strategies for treatment. Specialty Centers, often focusing on more complex conditions, such as oncology or rare diseases, further amplify the market's growth by providing targeted therapies and specialized care, bolstered by advancements in research and technology. The dominance of these healthcare settings stems from their ability to deliver comprehensive treatment options while addressing specific patient needs. These facilities not only enhance patient accessibility to innovative treatments but also foster the development of personalized medicine approaches. As the landscape of protein therapeutics continues to evolve, the role of Hospitals and Clinics, along with Specialty Centers, remains crucial in shaping patient outcomes and driving the growth of the US Protein Therapeutics Market. ## **US Protein Therapeutics Market Key Players and Competitive Insights** The competitive landscape of the US Protein Therapeutics Market is characterized by a dynamic interplay of established players, innovative startups, and a constant influx of research and development aimed at advancing protein-based therapeutics. As the market continues to evolve, driven by technological advancements and an increasing focus on precision medicine, companies in this sector are vying to leverage their unique capabilities to capture market share. This includes not only a focus on high-quality therapeutic proteins, such as monoclonal antibodies and recombinant proteins but also the development of biosimilars as a cost-effective alternative to branded therapeutics. The overall growth in biopharmaceuticals, heightened regulatory scrutiny, and patient-centered initiatives are shaping strategic decisions and competitive positioning among key players in the market. Genentech holds a prominent position within the US Protein Therapeutics Market, leveraging its extensive research capabilities and a robust portfolio of protein-based therapies. With several groundbreaking products that have transformed the treatment landscape for various diseases, Genentech has established itself as a leader through continuous innovation and a commitment to addressing unmet medical needs. The company has effectively utilized its strong brand recognition and established relationships with healthcare providers to solidify its presence across diverse therapeutic areas, including oncology and immunology. Genentech’s ability to navigate complex clinical pathways and regulatory approvals has allowed it to maintain a competitive edge, and its emphasis on patient-centric strategies drives loyalty and market penetration. In the context of the US Protein Therapeutics Market, Novartis has emerged as a significant force, recognized for its cutting-edge products and relentless pursuit of innovation in protein therapeutics. The company's portfolio includes key therapeutic proteins that address critical health challenges, positioning Novartis as a leader in the industry. With a strong emphasis on research and development, Novartis has actively pursued mergers and acquisitions to enhance its capabilities and expand its product offerings in the US market. This strategy has enabled Novartis to deliver advanced therapeutic solutions that are not only efficacious but also address the evolving needs of patients and healthcare systems. The firm’s focus on delivering value through its products, combined with a well-established distribution network, enhances its competitive stature within the growing protein therapeutics landscape, fostering partnerships with healthcare professionals and stakeholders committed to improving patient outcomes. ### **Key Companies in the US Protein Therapeutics Market Include** ## **US Protein Therapeutics Market Industry Developments** The US Protein Therapeutics Market continues to experience significant developments, with companies like Genentech, Novartis, and Merck and Co. leading the charge in innovative therapeutics. In September 2023, Eli Lilly received FDA approval for its new diabetes drug, enhancing its offerings in the protein therapeutics sector. Recent growth in market valuations for companies such as Bristol Myers Squibb and Gilead Sciences reflects increased demand for biologic therapies, pushing market dynamics toward high-value solutions. In August 2023, Regeneron Pharmaceuticals announced its acquisition of Checkmate Pharmaceuticals, strengthening its oncology portfolio. Pfizer and Amgen are investing heavily in Research and Development, focusing on novel protein-based therapies for chronic diseases. Furthermore, Roche and AbbVie have been actively involved in expanding their therapeutic applications in autoimmune disorders and cancer treatment, contributing to the market's resilience. Over the past two years, the market has seen transformative shifts, including groundbreaking approvals and partnerships that improve patient outcomes. The pharmaceutical landscape remains competitive, with major players adapting to regulatory changes and emphasizing patient-centric initiatives, underscoring the vibrant growth trajectory that characterizes the US Protein Therapeutics Market. ## **US Protein Therapeutics Market Segmentation Insights** ### **Protein Therapeutics Market Type Outlook** ### **Protein Therapeutics Market Application Outlook** ### **Protein Therapeutics Market End User Outlook** ## Market Drivers ### Increasing Demand for Biologics The protein therapeutics market is experiencing a notable surge in demand for biologics, which are derived from living organisms. This trend is largely driven by the growing prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders. According to recent estimates, the biologics segment is projected to account for over 40% of the total pharmaceutical market in the US by 2026. This increasing demand for biologics is compelling pharmaceutical companies to invest heavily in research and development, thereby propelling the growth of the protein therapeutics market. Furthermore, advancements in biotechnology are enabling the development of more effective and targeted therapies, which are likely to enhance patient outcomes and drive market expansion. ### Rising Investment in Biotechnology Investment in biotechnology is a critical driver of the protein therapeutics market. Venture capital funding for biotech firms has seen a substantial increase, with investments reaching approximately $20 billion in 2025 alone. This influx of capital is enabling companies to advance their research and development efforts, particularly in the field of protein therapeutics. Additionally, partnerships between biotech firms and larger pharmaceutical companies are becoming more common, facilitating the sharing of resources and expertise. This collaborative approach is likely to accelerate the development of innovative therapies, thereby enhancing the overall growth trajectory of the protein therapeutics market. As the biotechnology sector continues to thrive, it is expected to have a lasting impact on the protein therapeutics landscape. ### Growing Awareness of Personalized Medicine The increasing awareness of personalized medicine is significantly influencing the protein therapeutics market. Patients and healthcare providers are becoming more informed about the benefits of tailored therapies that cater to individual genetic profiles. This shift towards personalized treatment approaches is driving demand for protein therapeutics that can be customized to meet specific patient needs. As a result, pharmaceutical companies are focusing on developing targeted therapies that leverage genetic and molecular insights. The market for personalized medicine is projected to grow at a CAGR of over 10% through 2027, indicating a strong trend towards individualized treatment options. This growing emphasis on personalized medicine is likely to reshape the protein therapeutics market, fostering innovation and enhancing patient outcomes. ### Technological Advancements in Drug Development Technological innovations are playing a pivotal role in shaping the protein therapeutics market. The advent of advanced techniques such as CRISPR gene editing, monoclonal antibody technology, and high-throughput screening is revolutionizing the way new therapeutics are developed. These technologies not only expedite the drug discovery process but also improve the precision and efficacy of protein therapeutics. As a result, the market is witnessing a shift towards more sophisticated and targeted treatment options. The integration of artificial intelligence and machine learning in drug development is also expected to enhance the efficiency of clinical trials, potentially reducing the time to market for new therapies. This technological evolution is likely to attract significant investments, further stimulating growth in the protein therapeutics market. ### Regulatory Support and Streamlined Approval Processes The protein therapeutics market is benefiting from increased regulatory support and streamlined approval processes. Regulatory agencies, such as the FDA, are implementing initiatives aimed at expediting the review and approval of biologics and biosimilars. For instance, the FDA's 21st Century Cures Act has introduced measures to facilitate faster access to innovative therapies. This supportive regulatory environment is encouraging pharmaceutical companies to invest in the development of new protein therapeutics. Moreover, the establishment of clear guidelines for biosimilars is likely to enhance market competition, ultimately benefiting patients through increased access to affordable treatment options. As a result, the protein therapeutics market is expected to experience robust growth in the coming years. ## Future Outlook The [Protein Therapeutics Market](https://www.marketresearchfuture.com/reports/protein-therapeutics-market-10142) is projected to grow at a 7.36% CAGR from 2025 to 2035, driven by advancements in biotechnology, increasing chronic disease prevalence, and personalized medicine. **New opportunities:** - Development of biosimilars to enhance market access and affordability. - - Investment in AI-driven drug discovery platforms for faster therapeutic development. - Expansion of cold chain logistics to ensure product integrity during distribution. By 2035, the protein therapeutics market is projected to achieve substantial growth and innovation. ## Segment Insights ### By Type: Monoclonal Antibodies (Largest) vs. Recombinant Proteins (Fastest-Growing) The US protein therapeutics market is predominantly driven by Monoclonal Antibodies, which hold the largest market share among the segment values. This category has benefited from advancements in biotechnology and a growing demand for targeted therapies, giving it a significant edge in the market landscape. In contrast, Recombinant Proteins, although not leading, are rapidly gaining traction due to their increasing application in therapies and the growing pipeline of product approvals. Growth trends indicate that Monoclonal Antibodies will continue to be a cornerstone of the US protein therapeutics market, fueled by an expanding patient base and continuous innovation in drug development. Meanwhile, the rapid growth of Recombinant Proteins is driven by their versatility in treating various conditions and the increasing focus on personalized medicine, positioning them as a key area of interest for investors and developers alike. Monoclonal Antibodies (Dominant) vs. Recombinant Proteins (Emerging) Monoclonal Antibodies represent a dominant force in the US protein therapeutics market, characterized by their specificity and effectiveness in targeting disease pathways. They are extensively used in oncology, autoimmune diseases, and infectious diseases, showcasing their therapeutic versatility and high clinical efficacy. On the other hand, Recombinant Proteins are emerging as a vital component due to their application in a wide array of conditions, including hormonal imbalances and certain genetic disorders. The advancements in recombinant DNA technology allow for the production of more effective and safer therapeutic proteins, providing opportunities for growth in this segment. ### By Application: Oncology (Largest) vs. Autoimmune Diseases (Fastest-Growing) In the US protein therapeutics market, the application segment is largely dominated by oncology, which captures a significant market share due to increasing incidences of cancer and advancements in treatment options. Autoimmune diseases, while holding a smaller share, are rapidly gaining traction as more targeted therapies are developed, making it a critical area for investment. Growth trends indicate that the oncology segment continues to benefit from robust research & development efforts, with increasing FDA approvals for new therapies. In contrast, the autoimmune diseases sector is witnessing an accelerated growth trajectory due to rising awareness and diagnosis of these conditions. This has been fueled by innovations in biologics and personalized medicine, enhancing treatment efficacy and patient compliance. Oncology (Dominant) vs. Autoimmune Diseases (Emerging) Oncology is positioned as the dominant application in the US protein therapeutics market, characterized by a well-established presence of biologics and monoclonal antibodies targeting various cancer types. This segment benefits from continuous research and substantial funding, driving innovations in treatment modalities. Conversely, autoimmune diseases represent an emerging segment that is rapidly evolving, fueled by a growing number of therapeutic options. This area includes treatments aimed at conditions such as rheumatoid arthritis and multiple sclerosis. The increasing prevalence of autoimmune disorders and advancements in biologic therapies are pivotal in shaping this segment, attracting significant interest from both healthcare providers and pharmaceutical companies. ### By End Use: Hospital (Largest) vs. Research Laboratories (Fastest-Growing) In the segment of the US protein therapeutics market, hospitals hold the largest share, driven by their extensive need for various therapeutic proteins to treat a wide range of medical conditions. Research laboratories, while smaller in market share, are rapidly gaining ground owing to increasing investment in research and development of new therapeutics. The growth trends indicate that hospitals will continue to dominate due to the rising prevalence of chronic diseases and the expanding need for advanced therapeutic options. Conversely, research laboratories are emerging as a vital segment, fueled by innovations in biotechnology and a surge in collaborations between academic institutions and pharmaceutical companies, which accelerates the development of novel protein therapeutics. Hospital (Dominant) vs. Research Laboratories (Emerging) The hospital segment in the US protein therapeutics market remains dominant due to its critical role in patient care and the increasing demand for effective treatments. Hospitals are equipped with advanced infrastructure and resources that facilitate the use of protein therapeutics in diverse therapeutic areas, including oncology and immunotherapy. On the other hand, research laboratories are viewed as an emerging segment, leveraging cutting-edge technology and methodologies to innovate and facilitate the discovery of new therapeutic proteins. These laboratories play a pivotal role in clinical trials and drug development, driving trends that support the expansion of protein therapeutics, making them essential for future healthcare advancements. ### By Mode of Administration: Intravenous (Largest) vs. Subcutaneous (Fastest-Growing) The market share distribution among the different modes of administration in the US protein therapeutics market indicates that intravenous administration holds the largest share, predominantly due to its widespread application in hospital settings for immediate therapeutic effects. Subcutaneous administration, while currently smaller in comparison, is rapidly gaining traction, particularly in the chronic disease management and patient home care segments. Intramuscular administration remains a traditional choice, catering to specific therapeutic needs but doesn’t show the same growth momentum as subcutaneous alternatives. Growth trends for the modes of administration in the US protein therapeutics market are influenced by increasing patient preferences for less invasive options, particularly subcutaneous routes, which offer ease of use and improved patient compliance. The shift toward decentralized healthcare and home-based therapies further drives the adoption of subcutaneous administration. Conversely, intravenous remains essential for urgent care and complex protein therapeutics that require rapid absorption, maintaining its significant market position. Mode of Administration: Intravenous (Dominant) vs. Subcutaneous (Emerging) Intravenous administration is characterized by its ability to provide rapid drug delivery and is commonly used in acute care settings such as hospitals for conditions that require immediate medical intervention. This method allows for precise control over dosing and therapeutic response, making it indispensable for many medical professionals. On the other hand, subcutaneous administration is emerging as a popular alternative, especially for chronic conditions like diabetes and rheumatoid arthritis, where patient autonomy and ease of administration are crucial. This method of administration not only enhances patient convenience but also allows for self-administration, which is increasingly appealing in today's healthcare landscape. ## Competitive Benchmarking The protein therapeutics market is characterized by a dynamic competitive landscape, driven by innovation, strategic partnerships, and a focus on addressing unmet medical needs. Major players such as Amgen (US), Genentech (US), and AbbVie (US) are at the forefront, leveraging their extensive research capabilities and established market presence to enhance their product offerings. Amgen (US) emphasizes biopharmaceutical innovation, particularly in oncology and inflammatory diseases, while Genentech (US) focuses on personalized medicine and targeted therapies. AbbVie (US) is strategically positioned through its robust pipeline and recent acquisitions, which bolster its therapeutic portfolio, particularly in immunology and oncology. Collectively, these strategies contribute to a competitive environment that is increasingly focused on advanced therapeutic solutions and patient-centric approaches.Key business tactics within the protein therapeutics market include localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness. The market structure appears moderately fragmented, with a mix of established players and emerging biotech firms. The collective influence of key players shapes market dynamics, as they engage in strategic collaborations and partnerships to expand their reach and capabilities. This collaborative approach not only enhances product development but also fosters innovation across the sector. In October Amgen (US) announced a strategic partnership with a leading AI firm to enhance its drug discovery processes. This collaboration aims to integrate artificial intelligence into the research and development phases, potentially accelerating the identification of novel therapeutic candidates. The strategic importance of this move lies in Amgen's commitment to leveraging cutting-edge technology to maintain its competitive edge in a rapidly evolving market. In September Genentech (US) launched a new biosimilar product aimed at increasing access to critical therapies for patients with chronic conditions. This initiative reflects Genentech's strategy to diversify its product portfolio while addressing cost concerns in the healthcare system. The introduction of biosimilars is likely to enhance competition and drive down prices, thereby benefiting patients and healthcare providers alike. In August AbbVie (US) completed the acquisition of a biotech company specializing in gene therapy, significantly expanding its capabilities in the protein therapeutics space. This acquisition is strategically important as it positions AbbVie to tap into the growing gene therapy market, which is expected to witness substantial growth in the coming years. By integrating these advanced technologies, AbbVie aims to enhance its therapeutic offerings and solidify its market position. As of November current competitive trends in the protein therapeutics market are increasingly defined by digitalization, sustainability, and the integration of AI technologies. Strategic alliances are shaping the landscape, enabling companies to pool resources and expertise to drive innovation. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This shift underscores the importance of agility and responsiveness in meeting the evolving needs of patients and healthcare systems. ## Recent News & Developments The US Protein Therapeutics Market continues to experience significant developments, with companies like Genentech, Novartis, and Merck and Co. leading the charge in innovative therapeutics. In September 2023, Eli Lilly received FDA approval for its new diabetes drug, enhancing its offerings in the protein therapeutics sector. Recent growth in market valuations for companies such as Bristol Myers Squibb and Gilead Sciences reflects increased demand for biologic therapies, pushing market dynamics toward high-value solutions. In August 2023, Regeneron Pharmaceuticals announced its acquisition of Checkmate Pharmaceuticals, strengthening its oncology portfolio. Pfizer and Amgen are investing heavily in Research and Development, focusing on novel protein-based therapies for chronic diseases. Furthermore, Roche and AbbVie have been actively involved in expanding their therapeutic applications in autoimmune disorders and cancer treatment, contributing to the market's resilience. Over the past two years, the market has seen transformative shifts, including groundbreaking approvals and partnerships that improve patient outcomes. The pharmaceutical landscape remains competitive, with major players adapting to regulatory changes and emphasizing patient-centric initiatives, underscoring the vibrant growth trajectory that characterizes the US Protein Therapeutics Market. ## Report Scope | MARKET SIZE 2024 | 46.74(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 50.18(USD Billion) | | MARKET SIZE 2035 | 102.08(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.36% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | Amgen (US), Genentech (US), AbbVie (US), Roche (CH), Bristol-Myers Squibb (US), Eli Lilly (US), Sanofi (FR), Merck & Co. (US), Novo Nordisk (DK) | | Segments Covered | Type, Application, End Use, Mode of Administration | | Key Market Opportunities | Advancements in biologics manufacturing enhance efficiency in the protein therapeutics market. | | Key Market Dynamics | Rising demand for innovative protein therapeutics drives competitive dynamics and regulatory adaptations in the market. | | Countries Covered | US | ## Frequently Asked Questions **Q: What is the current valuation of the US protein therapeutics market?** A: The market valuation was $46.74 Billion in 2024. **Q: What is the projected market size for the US protein therapeutics market by 2035?** A: The projected valuation for 2035 is $102.08 Billion. **Q: What is the expected CAGR for the US protein therapeutics market during 2025 - 2035?** A: The expected CAGR during this period is 7.36%. **Q: Which companies are the key players in the US protein therapeutics market?** A: Key players include Amgen, Genentech, AbbVie, Roche, Bristol-Myers Squibb, Eli Lilly, Sanofi, Merck & Co., and Novo Nordisk. **Q: What are the main segments of the US protein therapeutics market?** A: The main segments include Monoclonal Antibodies, Recombinant Proteins, Hormones, and Vaccines. **Q: How much did the Monoclonal Antibodies segment generate in 2024?** A: The Monoclonal Antibodies segment generated $20.0 Billion in 2024. **Q: What is the projected growth for the Recombinant Proteins segment by 2035?** A: The Recombinant Proteins segment is projected to grow to $25.0 Billion by 2035. **Q: What applications dominate the US protein therapeutics market?** A: Dominant applications include Oncology, Autoimmune Diseases, Infectious Diseases, and Metabolic Disorders. **Q: What was the market size for the Autoimmune Diseases application in 2024?** A: The market size for Autoimmune Diseases was $10.0 Billion in 2024. **Q: What is the expected market size for the Subcutaneous mode of administration by 2035?** A: The Subcutaneous mode of administration is expected to reach $45.0 Billion by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-protein-therapeutics-market-19703*